SLC1A5 and neoplasm: It is reported that the anti-tumor activity of ASCT2 inhibitors does not necessarily correlate with the expression of transporter proteins (Schulte et al., 2018), and tumor cells that are sensitive to ASCT2 inhibitors are mainly susceptive to glutamine withdrawal (Schulte et al., 2018; Hara et al., 2020).